In Brief This Week: iGenix, Illumina; Sigma-Aldrich; Becton Dickinson; UK's National Cancer Research Institute; SRU Biosystems | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Seattle-based iGenix has been named an Illumina certified service provider for the BeadXpress platform. iGenix said that it specializes in biomarker evaluation and helps clients develop new diagnostic assays for the BeadXpress platform.


Sigma-Aldrich said this week that its board of directors has declared a quarterly cash dividend of $.16 per share to be payable on Dec. 15 to shareholders of record on Dec. 1.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.